Product Code: BT 6015
"The global flow cytometry market is projected to grow at a CAGR of 8.3%."
The global flow cytometry market size is projected to reach USD 6.4 billion by 2025 from USD 4.0 billion in 2019, growing at a CAGR of 8.3% from 2019 to 2025. The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing focus on immunology and immuno-oncology research, increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software, high incidence and prevalence of target diseases, and the availability of novel products.
"The bead-based technology segment is expected to grow at the fastest rate during the forecast period."
By technology, the flow cytometry market is classified into cell-based and bead-based. In 2019, the cell-based flow cytometry segment accounted for the largest share of the market. However, the bead-based flow cytometry segment is expected to grow at the highest CAGR during the forecast period. The growth of the bead-based flow cytometry segment can be attributed to the procedural advantages offered by this technology over other cell-based technology, such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.
"The reagents and consumables segment is expected to grow at the highest CAGR during 2019-2025."
On the basis of product and service, the flow cytometry market is categorized into reagents and consumables, instruments, services, software, and accessories. The reagents and consumables segment is expected to witness the highest growth during the forecast period due to the development and commercialization of high-quality application-specific reagents and assays and continuous requirement of flow cytometry reagents by end users (due to the increasing number of flow cytometry-based research activities).
"The Asia Pacific to witness the highest growth during the forecast period (2019-2025)"
North America is expected to hold the largest share of the global flow cytometry market in 2019 followed by Europe. However, the Asia Pacific is expected to grow at the fastest rate during the forecast period. The increasing participation of China, India, Japan, Australia, and South Korea in flow cytometry-based research; expansion of research infrastructure in the region; and public-private finding aimed towards boosting advance research practices are the key factors responsible for the growth of this market in the Asia Pacific.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1-33%, Tier 2-46%, and Tier 3-21%
- By Designation: C-level-26%, Director-level-20%, and Others-54%
- By Region: North America-33%, Europe-29%, APAC-24%, and RoW-14%
The major players in the market include: Becton, Dickinson and Company (US), Beckman Coulter, Inc. (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Sysmex Partec GmbH (Germany), Luminex Corporation (US), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (US), Sony Biotechnology, Inc. (US), Agilent Technologies, Inc. (US), bioMerieux S.A. (France), Enzo Life Sciences, Inc. (US), Stratedigm, Inc. (US), Cytonome/ST LLC (US), Cytek Biosciences (US), and Apogee Flow Systems Ltd. (UK).
Research Coverage:
This report studies the flow cytometry market based on technology, product and service, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of market segments with respect to four main regions (and the respective countries in these regions).
Key Benefits of Buying the Report:
This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the flow cytometry market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY USED FOR THE STUDY
- 1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 Breakdown of primaries
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
- 2.2.2 USAGE-BASED MARKET ESTIMATION
- 2.2.3 PRIMARY RESEARCH VALIDATION
- 2.3 DATA TRIANGULATION METHODOLOGY
- 2.4 RESEARCH ASSUMPTIONS
- 2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 FLOW CYTOMETRY: MARKET OVERVIEW
- 4.2 FLOW CYTOMETRY PRODUCTS & SERVICES MARKET, 2019 VS. 2025
- 4.3 FLOW CYTOMETRY MARKET, BY APPLICATION, 2019 VS. 2025
- 4.4 FLOW CYTOMETRY MARKET, BY END USER, 2019 VS. 2025
- 4.5 GEOGRAPHICAL SNAPSHOT OF THE FLOW CYTOMETRY MARKET
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Technological advancements
- 5.2.1.2 Increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software
- 5.2.1.3 Growing adoption of flow cytometry techniques in research and academia
- 5.2.1.4 Growing public-private initiatives in the field of immunology and immuno-oncology research
- 5.2.1.5 Rising global incidence and prevalence of HIV/AIDS and cancer
- 5.2.1.6 Increased availability of application-specific products
- 5.2.2 RESTRAINTS
- 5.2.2.1 Significant product costs
- 5.2.2.2 Limited purchasing power of end users in emerging countries
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Growing market presence in emerging countries
- 5.2.3.2 Evolving pipeline for stem cell research
- 5.2.3.3 Adoption of recombinant DNA technology for antibody production
- 5.2.3.4 Evolution of tandem flow cytometry technologies
- 5.2.4 CHALLENGES
- 5.2.4.1 Inadequate infrastructure for research in emerging countries
- 5.2.4.2 Complexities related to reagent development
- 5.2.4.3 Dearth of well-trained and skilled professionals
- 5.3 REGULATORY CHALLENGES
- 5.3.1 STRINGENT FDA REQUIREMENTS
- 5.3.2 STRINGENT ANALYTE-SPECIFIC REAGENT RULE
- 5.3.3 LACK OF WELL-DEFINED VALIDATION PROTOCOLS FOR CELL-BASED ASSAYS
- 5.3.4 ABSENCE OF ESTABLISHED LABORATORY-DEVELOPED TEST GUIDELINES ON CELL-BASED FLUORESCENCE ASSAYS
- 5.3.5 GREATER GLOBAL RECOGNITION FOR IVD-CE MARK APPROVALS
- 5.4 US REIMBURSEMENT SCENARIO
6 FLOW CYTOMETRY MARKET, BY TECHNOLOGY
- 6.1 INTRODUCTION
- 6.2 CELL-BASED FLOW CYTOMETRY
- 6.2.1 RESEARCH & DEVELOPMENT ON NOVEL THERAPEUTIC AGENTS WILL DRIVE THE GROWTH OF THE CELL-BASED FLOW CYTOMETRY MARKET
- 6.3 BEAD-BASED FLOW CYTOMETRY
- 6.3.1 PROCEDURAL ADVANTAGES OF BEAD-BASED FLOW CYTOMETRY HAVE DRIVEN MARKET GROWTH
7 FLOW CYTOMETRY MARKET, BY PRODUCT & SERVICE
- 7.1 INTRODUCTION
- 7.2 REAGENTS & CONSUMABLES
- 7.2.1 REAGENTS AND CONSUMABLES WILL GENERATE THE HIGHEST REVENUE IN THE FLOW CYTOMETRY MARKET DURING THE FORECAST PERIOD
- 7.3 FLOW CYTOMETRY INSTRUMENTS
- 7.3.1 CELL ANALYZERS
- 7.3.1.1 High-range cell analyzers
- 7.3.1.1.1 High-range cell analyzers account for the largest share of the cell analyzers market
- 7.3.1.2 Mid-range cell analyzers
- 7.3.1.2.1 Wide availability of compact and high-performance analyzers in this price range support market growth
- 7.3.1.3 Low-range cell analyzers
- 7.3.1.3.1 Low-range analyzers find significant adoption among price-sensitive end users
- 7.3.2 CELL SORTERS
- 7.3.2.1 High-range cell sorters
- 7.3.2.1.1 High-range cell sorters dominate the market
- 7.3.2.2 Mid-range cell sorters
- 7.3.2.2.1 Product launches and the cost-efficiency of mid-range sorters have enabled the growth of this market segment
- 7.3.2.3 Low-range cell sorters
- 7.3.2.3.1 Increasing commercialization of affordable products has driven the adoption of low-range cell sorters
- 7.4 SERVICES
- 7.4.1 CUSTOM FLOW CYTOMETRY ASSAY DEVELOPMENT SERVICES HAVE HELPED IN THE ADVANCEMENT OF RESEARCH, ESPECIALLY IN CELL BIOLOGY
- 7.5 SOFTWARE
- 7.5.1 AVAILABILITY OF A WIDE RANGE OF ANALYSIS SOFTWARE AND ADVANCEMENTS ARE DRIVING MARKET GROWTH
- 7.6 ACCESSORIES
8 FLOW CYTOMETRY MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 RESEARCH APPLICATIONS
- 8.2.1 PHARMACEUTICALS & BIOTECHNOLOGY
- 8.2.1.1 Drug discovery
- 8.2.1.1.1 Wide usage of flow cytometry in drug discovery is the primary driver of market growth
- 8.2.1.2 Stem cell research
- 8.2.1.2.1 Accuracy and precision of flow cytometry have made it a prominent tool in stem cell research
- 8.2.1.3 In vitro toxicity testing
- 8.2.1.3.1 Need to reduce time and cost of drug development processes will be a key factor driving market growth
- 8.2.2 IMMUNOLOGY
- 8.2.2.1 Flow cytometry plays a vital role in immunology studies
- 8.2.3 CELL SORTING
- 8.2.3.1 Increase in cell-based research activity has boosted growth in this application segment
- 8.2.4 APOPTOSIS
- 8.2.4.1 Flow cytometry techniques are used to identify changes occurring during apoptosis
- 8.2.5 CELL CYCLE ANALYSIS
- 8.2.5.1 Any abnormality in DNA content can be detected using flow cytometry
- 8.2.6 CELL VIABILITY
- 8.2.6.1 Cell viability is a key parameter studied using flow cytometry
- 8.2.7 CELL COUNTING
- 8.2.7.1 Flow cytometry allows for easy differentiation of cells via scattering or staining
- 8.2.8 OTHER RESEARCH APPLICATIONS
- 8.3 CLINICAL APPLICATIONS
- 8.3.1 CANCER
- 8.3.1.1 Cancer applications include the determination of tumor malignancy and chromosome enumeration
- 8.3.2 HEMATOLOGY
- 8.3.2.1 Flow cytometry can help identify a wide variety of cell surfaces and cytoplasmic antigens
- 8.3.3 IMMUNODEFICIENCY DISEASES
- 8.3.3.1 Flow cytometry allows for simultaneous, multi-parametric cell analysis
- 8.3.4 ORGAN TRANSPLANTATION
- 8.3.4.1 Use of flow cytometry to reduce organ rejection rates has contributed to market growth
- 8.3.5 OTHER CLINICAL APPLICATIONS
- 8.4 INDUSTRIAL APPLICATIONS
- 8.4.1 WIDE END-USER BASE WILL DRIVE MARKET GROWTH
9 FLOW CYTOMETRY MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 ACADEMIC & RESEARCH INSTITUTES
- 9.2.1 GROWING NUMBER OF RESEARCH PROJECTS THROUGH INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET GROWTH
- 9.3 HOSPITALS & CLINICAL TESTING LABORATORIES
- 9.3.1 RISING AWARENESS AND DISEASE PREVALENCE HAVE SUSTAINED THE DEMAND FOR FLOW CYTOMETRY IN HOSPITALS
- 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.4.1 INCREASE IN DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH
10 FLOW CYTOMETRY MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.1.1 Technological innovation and strategic collaborations are the key drivers of market growth in the US
- 10.2.2 CANADA
- 10.2.2.1 Availability of public and private funding for research activities will boost demand for flow cytometry products in Canada
- 10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.1.1 Strong R&D infrastructure and training and awareness programs have ensured market growth in Germany
- 10.3.2 UK
- 10.3.2.1 UK to witness growing acceptance of flow cytometry products for clinical diagnostics
- 10.3.3 FRANCE
- 10.3.3.1 Training and awareness programs by social organizations and key players are expected to fuel the adoption of flow cytometry
- 10.3.4 ITALY
- 10.3.4.1 Growing use of clinical flow cytometry will favor market growth
- 10.3.5 SPAIN
- 10.3.5.1 High instrument costs and funding limitations have slowed market growth in Spain
- 10.3.6 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 JAPAN
- 10.4.1.1 Strong infrastructure and favorable market outlook have sustained Japan's dominance in the APAC market
- 10.4.2 CHINA
- 10.4.2.1 China accounts for the second-largest share of the APAC market
- 10.4.3 INDIA
- 10.4.3.1 High incidence of HIV/AIDS and cancer drives demand for flow cytometry instruments in India
- 10.4.4 AUSTRALIA
- 10.4.4.1 Rise in cancer prevalence and awareness on flow cytometry have favored the growth of the Australian market
- 10.4.5 SOUTH KOREA
- 10.4.5.1 Rising awareness and the growing presence of players are driving market growth
- 10.4.6 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 BRAZIL
- 10.5.1.1 Brazil dominates the LATAM market for flow cytometry
- 10.5.2 MEXICO
- 10.5.2.1 Free trade agreements will support imports and accessibility to flow cytometry instruments in Mexico
- 10.5.3 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST AND AFRICA
- 10.6.1 LOW DISPOSABLE INCOME AND NEED FOR INFRASTRUCTURAL DEVELOPMENT HINDER MARKET GROWTH
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 COMPETITIVE LEADERSHIP MAPPING
- 11.3 COMPETITIVE LEADERSHIP MAPPING: MAJOR MARKET PLAYERS (2018)
- 11.3.1 VISIONARY LEADERS
- 11.3.2 INNOVATORS
- 11.3.3 DYNAMIC DIFFERENTIATORS
- 11.3.4 EMERGING COMPANIES
- 11.4 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2018)
- 11.4.1 PROGRESSIVE COMPANIES
- 11.4.2 STARTING BLOCKS
- 11.4.3 RESPONSIVE COMPANIES
- 11.4.4 DYNAMIC COMPANIES
- 11.5 COMPETITIVE SCENARIO (2016-2019)
- 11.5.1 KEY PRODUCT LAUNCHES AND APPROVALS (2016-2019)
- 11.5.2 KEY AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2016-2019)
- 11.5.3 KEY ACQUISITIONS (2016-2019)
- 11.5.4 KEY EXPANSIONS (2016-2019)
- 11.6 GLOBAL MARKET SHARE ANALYSIS, TOP THREE MARKET PLAYERS (2018)
12 COMPANY PROFILES
(Business overview, Products offered, Recent developments, MNM view)*
- 12.1 BECTON, DICKINSON AND COMPANY
- 12.2 BECKMAN COULTER (A SUBSIDIARY OF DANAHER)
- 12.3 THERMO FISHER SCIENTIFIC
- 12.4 MERCK KGAA
- 12.5 LUMINEX CORPORATION
- 12.6 AGILENT TECHNOLOGIES
- 12.7 SONY BIOTECHNOLOGY (A SUBSIDIARY OF SONY CORPORATION OF AMERICA)
- 12.8 BIO-RAD LABORATORIES
- 12.9 MILTENYI BIOTEC
- 12.10 ENZO LIFE SCIENCES, INC. (A SUBSIDIARY OF ENZO BIOCHEM)
- 12.11 SYSMEX PARTEC (A SUBSIDIARY OF SYSMEX CORPORATION)
- 12.12 BIOMERIEUX SA
- 12.13 CYTONOME/ST, LLC
- 12.14 STRATEDIGM, INC.
- 12.15 APOGEE FLOW SYSTEMS
- 12.16 CYTEK BIOSCIENCES, INC.
- 12.17 OTHER COMPANIES
- 12.17.1 SARTORIUS AG
- 12.17.2 UNION BIOMETRICA, INC.
- 12.17.3 NANOCELLECT BIOMEDICAL, INC.
- 12.17.4 ON-CHIP BIOTECHNOLOGIES CO., LTD.
Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 AVAILABLE CUSTOMIZATIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
比較リスト
